CN102515576B - 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 - Google Patents
磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 Download PDFInfo
- Publication number
- CN102515576B CN102515576B CN201110397845.5A CN201110397845A CN102515576B CN 102515576 B CN102515576 B CN 102515576B CN 201110397845 A CN201110397845 A CN 201110397845A CN 102515576 B CN102515576 B CN 102515576B
- Authority
- CN
- China
- Prior art keywords
- cement
- magnesium oxide
- magnesium
- setting time
- different
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 title claims abstract description 161
- 239000000395 magnesium oxide Substances 0.000 title claims abstract description 85
- 239000004568 cement Substances 0.000 title claims abstract description 73
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 title claims abstract description 36
- 229910000157 magnesium phosphate Inorganic materials 0.000 title claims abstract description 34
- 239000004137 magnesium phosphate Substances 0.000 title claims abstract description 34
- 229960002261 magnesium phosphate Drugs 0.000 title claims abstract description 34
- 235000010994 magnesium phosphates Nutrition 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 title claims abstract 14
- 235000012245 magnesium oxide Nutrition 0.000 claims abstract description 85
- 239000000463 material Substances 0.000 claims abstract description 78
- 238000001354 calcination Methods 0.000 claims abstract description 59
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 230000009257 reactivity Effects 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 17
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 12
- 239000010452 phosphate Substances 0.000 claims abstract description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 11
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 7
- 238000003837 high-temperature calcination Methods 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 29
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 15
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 15
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 15
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 15
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 13
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 13
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 13
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 12
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 235000013922 glutamic acid Nutrition 0.000 claims description 9
- 239000004220 glutamic acid Substances 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 229920002307 Dextran Polymers 0.000 claims description 8
- QQFLQYOOQVLGTQ-UHFFFAOYSA-L magnesium;dihydrogen phosphate Chemical compound [Mg+2].OP(O)([O-])=O.OP(O)([O-])=O QQFLQYOOQVLGTQ-UHFFFAOYSA-L 0.000 claims description 8
- 229910000401 monomagnesium phosphate Inorganic materials 0.000 claims description 8
- 235000019785 monomagnesium phosphate Nutrition 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 235000011132 calcium sulphate Nutrition 0.000 claims description 5
- 239000001175 calcium sulphate Substances 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 239000012620 biological material Substances 0.000 abstract description 20
- 210000000988 bone and bone Anatomy 0.000 description 26
- 230000015556 catabolic process Effects 0.000 description 22
- 238000006731 degradation reaction Methods 0.000 description 22
- 206010017076 Fracture Diseases 0.000 description 12
- 239000000654 additive Substances 0.000 description 12
- 230000000996 additive effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000037237 body shape Effects 0.000 description 7
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 7
- YYRMJZQKEFZXMX-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca+2].OP(O)(O)=O.OP(O)(O)=O YYRMJZQKEFZXMX-UHFFFAOYSA-N 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000002426 superphosphate Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 150000003863 ammonium salts Chemical class 0.000 description 5
- 239000002639 bone cement Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000012779 reinforcing material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 231100000899 acute systemic toxicity Toxicity 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- -1 potassium ion Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical class CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- BYACHAOCSIPLCM-UHFFFAOYSA-N 2-[2-[bis(2-hydroxyethyl)amino]ethyl-(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCN(CCO)CCO BYACHAOCSIPLCM-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- 206010053206 Fracture displacement Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 238000005297 material degradation process Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000007712 rapid solidification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
样品 | 凝固时间/min | 压缩强度(12h)/MPa | 粘接强度(2h)/MPa |
A | 8.3 | 45 | 3.84 |
B | 7.9 | 37 | 3.58 |
压缩强度(12h)/Mpa | 粘结强度(2h)/Mpa | |
样品C | 39.6 | 3.64 |
样品D | 36.7 | 2.58 |
检测项目 | 技术要求 | 检测结果 | 结论 |
细胞毒性 | 细胞毒性反应不大于1级 | 增殖法:0-1级 | 合格 |
溶血 | 溶血率小于5% | 溶血率:1.4% | 合格 |
皮内刺激反应 | 无皮内刺激反应 | 刺激指数:0.0 | 合格 |
急性全身毒性 | 无急性全身毒性反应 | 无毒性反应 | 合格 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110397845.5A CN102515576B (zh) | 2011-12-05 | 2011-12-05 | 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110397845.5A CN102515576B (zh) | 2011-12-05 | 2011-12-05 | 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102515576A CN102515576A (zh) | 2012-06-27 |
CN102515576B true CN102515576B (zh) | 2016-03-30 |
Family
ID=46286720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110397845.5A Expired - Fee Related CN102515576B (zh) | 2011-12-05 | 2011-12-05 | 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102515576B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102488921B (zh) * | 2011-12-22 | 2013-10-16 | 韩大庆 | 与钾或镁离子具有螯合作用的物质在提高磷酸镁水泥生物相容性助剂中的应用及磷酸镁水泥 |
MX368918B (es) * | 2014-02-25 | 2019-10-21 | Konoshima Chemical | Granulos de oxido de magnesio para aplicaciones farmaceuticas o para uso como aditivos de alimentos. |
CN104740680B (zh) * | 2015-02-13 | 2017-01-25 | 苏州景卓生物技术有限公司 | 一种镁基生物材料组合物及其制备方法与应用 |
CN104744975B (zh) * | 2015-03-26 | 2017-09-01 | 深圳琦美龙新建材科技有限公司 | 一种磷酸镁无机隔热涂料及其制备方法 |
CN109749727A (zh) * | 2017-11-02 | 2019-05-14 | 中国石油化工股份有限公司 | 一种低温磷酸盐热固树脂胶凝体系及其制备方法 |
CN109749726A (zh) * | 2017-11-02 | 2019-05-14 | 中国石油化工股份有限公司 | 一种中温磷酸盐热固树脂胶凝体系及其制备方法 |
CN109749725A (zh) * | 2017-11-02 | 2019-05-14 | 中国石油化工股份有限公司 | 一种高温磷酸盐热固树脂胶凝体系及其制备方法 |
CN108658102B (zh) * | 2018-05-21 | 2020-10-02 | 西华师范大学 | 一种提高磷酸镁骨水泥生物相容性的氧化镁原料及其制备方法 |
CN111888521B (zh) * | 2020-06-11 | 2021-12-17 | 上海禾麦医学科技有限公司 | 骨修复材料及其制备方法 |
CN114621003A (zh) * | 2021-11-04 | 2022-06-14 | 上海市第八人民医院 | 一种改性羟基磷灰石、复合骨水泥及其制备方法和应用 |
CN114213047B (zh) * | 2021-12-31 | 2023-03-24 | 中国科学院青海盐湖研究所 | 一种高强磷硅酸镁水泥及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1307908A (zh) * | 2001-02-22 | 2001-08-15 | 华东理工大学 | 无机骨粘合剂及其在人体硬组织修复中的应用 |
WO2010071857A1 (en) * | 2008-12-19 | 2010-06-24 | Biomimetic Therapeutics, Inc. | Bone grafts with reduced protease activity and methods of selection and use |
-
2011
- 2011-12-05 CN CN201110397845.5A patent/CN102515576B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1307908A (zh) * | 2001-02-22 | 2001-08-15 | 华东理工大学 | 无机骨粘合剂及其在人体硬组织修复中的应用 |
WO2010071857A1 (en) * | 2008-12-19 | 2010-06-24 | Biomimetic Therapeutics, Inc. | Bone grafts with reduced protease activity and methods of selection and use |
Non-Patent Citations (2)
Title |
---|
无机骨粘固剂-磷酸镁骨水泥的研究进展;刘子胜等;《材料导报》;20000531;第14卷(第5期);29-32 * |
重烧氧化镁粉的活性测定;唐小丽等;《华东理工大学学报》;20010430;第27卷(第2期);157-160 * |
Also Published As
Publication number | Publication date |
---|---|
CN102515576A (zh) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102515576B (zh) | 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 | |
RU2379061C2 (ru) | Рассасывающиеся керамические композиции | |
CN106310363B (zh) | 一种可降解含镁和锌的磷酸钙-硫酸钙多孔复合生物支架 | |
Chow | Calcium phosphate cements: chemistry, properties, and applications | |
KR101769805B1 (ko) | 테트라 칼슘 포스페이트 기재 유기인계 조성물 및 방법 | |
EP1715829B1 (en) | Rapid-hardening calcium phosphate cement compositions | |
CN102580144B (zh) | 外科用骨水泥及其制造方法 | |
CN105731846B (zh) | 一种磷酸镁骨水泥 | |
CN104837512B (zh) | 可注射的、生物可降解的骨接合剂及其制造和使用方法 | |
JPH0222113A (ja) | リン酸カルシウム鉱物の製造方法 | |
JPH03174311A (ja) | 現場調製されたリン酸カルシウム鉱物のための貯蔵安定配合物 | |
BR122015011568B1 (pt) | misturas para formar um material cerâmico para uso em aplicações dentais e ortopédicas | |
Haque et al. | In vitro and in vivo research advancements on the magnesium phosphate cement biomaterials: A review | |
CN104591679A (zh) | 一种改性氯氧镁骨水泥及其制备方法和应用 | |
Dorozhkin | Self-setting calcium orthophosphate (CaPO4) formulations and their biomedical applications | |
US20130156864A1 (en) | Inorganic Cement for Biomedical uses, Preparation Method Thereof and Use of Same | |
US20060096504A1 (en) | Adhesive bone cement | |
CN102488921B (zh) | 与钾或镁离子具有螯合作用的物质在提高磷酸镁水泥生物相容性助剂中的应用及磷酸镁水泥 | |
JP2001314497A (ja) | 生体材料用組成物及びその硬化体 | |
CN103830774A (zh) | 一种新型骨水泥及其制备方法 | |
El-Maghraby et al. | Preparation, structural characterization, and biomedical applications of gypsum-based nanocomposite bone cements | |
Tofighi et al. | New generation of synthetic, bioresorbable and injectable calcium phosphate bone substitute materials: Alpha-bsm®, Beta-bsmTM and Gamma-bsmTM | |
Pijocha et al. | Effect of retardants on the heat release during setting of bone cement-type composites | |
Şahin | Synthesis and characterization of calcium phosphate cement based macroporous scaffolds | |
CN104107455A (zh) | 一种骨水泥及其浆体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HAN DAQING Free format text: FORMER OWNER: SUZHOU DAPU BIOLOGICAL TECHNOLOGY TECHNOLOGY CO., LTD. Effective date: 20130513 Free format text: FORMER OWNER: CHENGDU DAPU MEDICAL DEVICES CO., LTD. Effective date: 20130513 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215123 SUZHOU, JIANGSU PROVINCE TO: 110002 SHENYANG, LIAONING PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130513 Address after: 110002, 2-6-2, 13 East embroidered Street East, Tiexi District, Liaoning, Shenyang Applicant after: Han Daqing Address before: Suzhou City, Jiangsu province 215123 Industrial Park Suzhou Xinghu Street No. 218 Building 1 layer A5 Applicant before: SUZHOU DAPU BIOTECHNOLOGY CO.,LTD. Applicant before: CHENGDU DAPU MEDICAL DEVICES Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161031 Address after: 300380, building 10, building 35, 901, Xiqing Industrial Zone, Tianjin, China Patentee after: Tianjin magnesium Biological Technology Co.,Ltd. Address before: 13 2-6-2, 110002 East embroidery street, Tiexi District, Liaoning, Shenyang Patentee before: Han Daqing |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160330 Termination date: 20211205 |